Table 2.

Efficacy of different treatment regimens.

Tumor type	Treatment regimen	Objective response rate (ORR)	Disease control rate (DCR)	Progression - free survival (PFS, months)	Overall survival (OS, months)
Non - Small - Cell Lung Cancer	Pembrolizumab + Pemetrexed + Platinum - based Chemotherapy	47.6%	76.4%	8.8	19.2
Non - Small - Cell Lung Cancer	Traditional Chemotherapy (Pemetrexed + Platinum - based)	18.9%	49.4%	4.9	11.3
Non - Small - Cell Lung Cancer (EGFR - Mutated)	Osimertinib as First - Line Treatment	71%	93%	18.9	Immature
Non - Small - Cell Lung Cancer (ALK - Fusion - Positive)	Alectinib as First - Line Treatment	72.5%	96.2%	34.8	Not Reached
Non - Small - Cell Lung Cancer (HER2 - Mutated)	Trastuzumab Deruxtecan Treatment	58.3%	81.3%	8.2	17.8
Small - Cell Lung Cancer	Durvalumab in Consolidation Treatment after Concurrent Chemoradiotherapy	28.4%	66.3%	16.8	47.5
Small - Cell Lung Cancer	Traditional Concurrent Chemoradiotherapy (Etoposide + Platinum - based)	16.0%	41.0%	5.6	28.7
HER2 - Positive Breast Cancer	Trastuzumab + Chemotherapy	75%	89%	No Specific Single Data	No Specific Single Data
HER2 - Positive Breast Cancer	Dual - Target Combination of Pertuzumab and Trastuzumab	80.2%	93.8%	18.5	56.5
HER2 - Positive Breast Cancer (Brain Metastases)	DS - 8201 Treatment	64%	No Specific Single Data	No Specific Single Data	No Specific Single Data
Triple - Negative Breast Cancer	Sacituzumab Govitecan Monotherapy	35%	46%	4.8	11.8
Triple - Negative Breast Cancer (PD - L1 - Positive)	Pembrolizumab + Chemotherapy (Albumin - Bound Paclitaxel)	21% - 35%	No Specific Single Data	5.6	No Specific Single Data
Esophageal Cancer	Nivolumab + Chemotherapy (Fluorouracil + Platinum - based)	45.9%	72.5%	7.7	13.2
Esophageal Cancer	Traditional Chemotherapy (Fluorouracil + Platinum - based)	29.4%	55.7%	5.6	11.1